Psilocybin low dose - Apex Laboratories
Alternative Names: APEX-52Latest Information Update: 26 Jun 2024
Price :
$50 *
At a glance
- Originator Apex Laboratories
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anxiety disorders; Depressive disorders
Most Recent Events
- 20 Jun 2024 Apex Laboratories files an IND application with the US FDA in USA
- 20 Jun 2024 Apex Laboratories plans a phase I APEX-002-B01-02 pharmacokinetics trial in the US (PO)
- 07 Mar 2024 Apex Laboratories files for patent protection with the United States Patent and Trademark Office (USPTO) for unique capsule formulation in USA